Welcome to our dedicated page for Climb Bio news (Ticker: CLYM), a resource for investors and traders seeking the latest updates and insights on Climb Bio stock.
Climb Bio, Inc. develops therapeutics for patients with immune-mediated diseases. News about Climb Bio centers on its clinical-stage monoclonal antibody pipeline, including budoprutug, an anti-CD19 antibody for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia and systemic lupus erythematosus, and CLYM116, an anti-APRIL antibody for IgA nephropathy.
Recurring updates include clinical development progress, formulation data, regulatory actions such as FDA Fast Track Designation for budoprutug in primary membranous nephropathy, R&D presentations, business updates and operating results. Company announcements also cover financing activity, governance changes and investor communications tied to its biotechnology development strategy.
Climb Bio (Nasdaq: CLYM) will present new data on its CLYM116 and budoprutug programs at the European Renal Association (ERA) Congress 2026 in Glasgow, June 3-6, 2026.
Presentations cover PK/PD modeling and initial Phase 1 safety data for CLYM116 in IgA nephropathy and a Phase 2 trial-in-progress poster for budoprutug in primary membranous nephropathy.
Climb Bio (Nasdaq: CLYM) announced it will present new clinical data from its budoprutug program at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden, held June 11-14, 2026.
The poster will share safety, B-cell depletion and initial platelet data from the low-dose 250 mg cohort at 24 weeks in an ongoing Phase 1b/2a trial in adults with primary immune thrombocytopenia (ITP).
Climb Bio (Nasdaq: CLYM) announced participation in two upcoming investor conferences featuring executive team fireside chats.
Events include the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 11:00–11:30 a.m. ET, and the Jefferies Global Healthcare Conference on June 4, 2:35–3:05 p.m. ET, with live and replay webcasts on its website.
Climb Bio (Nasdaq: CLYM) reported Q1 2026 results and program updates on May 7, 2026. Key operational highlights include robust B-cell depletion from budoprutug subcutaneous Phase 1 data, multiple ongoing budoprutug trials with anticipated readouts across 2026, CLYM116 PK/PD modeling to be presented at ERA 2026, and a completed $110 million private placement.
Financials: cash, cash equivalents, and marketable securities of $146.3 million as of March 31, 2026; R&D expense of $9.4 million; G&A expense of $5.8 million; other income, net of $1.5 million.
Climb Bio (Nasdaq: CLYM) reported topline Phase 1 subcutaneous (SC) data for budoprutug showing robust B-cell depletion in healthy volunteers, comparable to IV at matched doses, and that SC was generally safe and well-tolerated. The company received Fast Track designation for pMN and expects initial clinical data across ITP (June 2026), pMN (Q4 2026), and SLE (Q4 2026).
Climb is advancing budoprutug (anti-CD19 mAb) in parallel IV and SC programs across pMN, ITP, and SLE with biomarker-driven designs and a webcast held May 5, 2026.
Climb Bio (Nasdaq: CLYM) entered a private placement to raise approximately $110.0 million in gross proceeds, expected to close on or about April 29, 2026, subject to customary closing conditions.
The company is selling 9,481,000 common shares at $9.50 per share and issued pre-funded warrants to purchase up to 2,106,000 shares at $9.4999 each (exercise price $0.0001). Placement agents include Leerink Partners and Piper Sandler; several institutional investors participated. Climb Bio agreed to file a resale registration statement with the SEC within 45 days after closing.
Climb Bio (Nasdaq: CLYM) will host an R&D Spotlight webcast on May 5, 2026 at 8:00 a.m. ET focused on budoprutug, an anti-CD19 monoclonal antibody for B-cell mediated diseases. The event will cover target rationale, clinical study design, dose selection, and development strategy.
Speakers include Climb Bio management and David Jayne, MD, Professor of Clinical Autoimmunity at the University of Cambridge. A replay will be available on the company's investor website about two hours after the live webcast and archived for at least 30 days.
Climb Bio (Nasdaq: CLYM) announced FDA Fast Track Designation for budoprutug to treat primary membranous nephropathy (pMN).
Budoprutug showed complete peripheral B-cell depletion in 100% (5/5) of Phase 1b patients, serologic remission in 3/3 evaluable patients, and complete/partial clinical remission in 5/5 by week 48. A global Phase 2 study (PrisMN) is enrolling; initial data expected H2 2026.
Climb Bio (Nasdaq: CLYM) reported Q4 and full-year 2025 results and clinical updates on March 5, 2026. The company ended 2025 with $160.7 million in cash and expects runway into 2028. Multiple budoprutug trials are underway, a subcutaneous dosing study completed, and several initial data readouts are expected across 2026.
CLYM116 Phase 1 enrollment continues with initial healthy-volunteer data anticipated mid-2026; IND clearance obtained in China for a parallel SLE study.
Climb Bio (Nasdaq: CLYM) announced that its executive team will present at three investor conferences in Feb–Mar 2026: Guggenheim Emerging Outlook: Biotech Summit on Feb 12, Oppenheimer Healthcare Life Sciences on Feb 25, and Leerink Global Healthcare on Mar 9.
The presentations are fireside chats with live webcasts available via the company’s Investors & Media website; replays will be posted about two hours after each event and archived for at least 30 days.